Cargando…

Minimal Impact of the COVID‐19 Pandemic on Disease Activity and Health‐Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open‐Label Extension Study

OBJECTIVE: The impact of the COVID‐19 pandemic on patients with inflammatory rheumatic diseases, such as ankylosing spondylitis (AS), has been variable. Here, we assess disease activity and health‐related quality of life (HRQoL) through the pandemic in patients with AS. METHODS: In the open‐label ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robinson, Philip C., Machado, Pedro M., Haroon, Nigil, Gensler, Lianne S., Reveille, John D., Taieb, Vanessa, Vaux, Thomas, Fleurinck, Carmen, Oortgiesen, Marga, de Peyrecave, Natasha, Deodhar, Atul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349833/ https://www.ncbi.nlm.nih.gov/pubmed/35833532 http://dx.doi.org/10.1002/acr2.11486

Ejemplares similares

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Editorial: Ankylosing Spondylitis and Related Immune-Mediated Disorders
por: Fiorillo, Maria Teresa, et al.
Publicado: (2019)

The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis
por: Tsui, Florence WL, et al.
Publicado: (2014)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Increasing proportion of female patients with ankylosing spondylitis: a population-based study of trends in the incidence and prevalence of AS
por: Haroon, Nisha N, et al.
Publicado: (2014)

Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis
por: Hwang, Mark C., et al.
Publicado: (2021)

Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis
por: Rudwaleit, Martin, et al.
Publicado: (2023)

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
por: Deodhar, Atul, et al.
Publicado: (2021)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

The risk of deliberate self-harm following a diagnosis of rheumatoid arthritis or ankylosing spondylitis: A population-based cohort study
por: Kuriya, Bindee, et al.
Publicado: (2020)

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study
por: Deodhar, Atul A., et al.
Publicado: (2022)

Acute mental health service use is increased in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study
por: Kuriya, Bindee, et al.
Publicado: (2020)

Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients
por: Stoll, Matthew L., et al.
Publicado: (2022)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2022)

Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study
por: Wallis, Dinny, et al.
Publicado: (2013)

A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis
por: Deodhar, A., et al.
Publicado: (2020)

ANKH variants associated with ankylosing spondylitis: gender differences
por: Tsui, Hing Wo, et al.
Publicado: (2005)

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2023)

Geographic Variations in Diagnosis and Treatment of Ankylosing Spondylitis in the United States: A Real-World Study
por: Deodhar, Atul, et al.
Publicado: (2021)

Persistence, Discontinuation, and Switching Patterns of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients in the United States
por: Hunter, Theresa, et al.
Publicado: (2019)

Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials
por: Gensler, L. S., et al.
Publicado: (2020)

Bimekizumab for plaque psoriasis
Publicado: (2022)

Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time
por: Doughem, Karim, et al.
Publicado: (2020)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study
por: Robinson, Philip C., et al.
Publicado: (2022)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort
por: Rahbar, Mohammad H., et al.
Publicado: (2018)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
por: Mundwiler, Matthew L, et al.
Publicado: (2009)

Correction: Stoll et al. Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients. Children 2022, 9, 569
por: Stoll, Matthew L., et al.
Publicado: (2022)

Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study
por: Matzkies, Franziska G, et al.
Publicado: (2012)

Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis
por: Hoepken, Bengt, et al.
Publicado: (2020)

Single Cell Transcriptome and Surface Epitope Analysis of Ankylosing Spondylitis Facilitates Disease Classification by Machine Learning
por: Alber, Samuel, et al.
Publicado: (2022)

Review of bimekizumab in the treatment of psoriasis
por: Koppu, Sindhuja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s88pnrkmku3ktjvl506l3udbi1